Trends in Immunotherapy

Mini-review

ER stress mediated inflammation in cancer pathogenesis

Downloads

https://doi.org/10.24294/ti.v8.i1.2531
S. Jalajakumari, S., Ramesh, R., & S. Nair, A. (2024). ER stress mediated inflammation in cancer pathogenesis. Trends in Immunotherapy, 8(1). https://doi.org/10.24294/ti.v8.i1.2531
Volume 8 Issue 1 (2024)
Copyright (c) 2024 Soumya S. Jalajakumari, Renu Ramesh, Achuthsankar S. Nair
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Soumya S. Jalajakumari
    Department of Computational Biology and Bioinformatics, University of Kerala, Thiruvananthapuram 695581, Kerala, India
  • Renu Ramesh Inter University Centre for Genomics and Gene Technology, University of Kerala, Thiruvananthapuram 695581, Kerala, India
  • Achuthsankar S. Nair Department of Computational Biology and Bioinformatics, University of Kerala, Thiruvananthapuram 695581, Kerala, India

Inflammation is a complex process which is associated with the initiation and progression of cancer. Prolonged Endoplasmic Reticulum (ER) stress triggers inflammation which is a key factor associated with cancer pathogenesis. ER stress also contributes to immune suppression in inflammatory and tumor microenvironment. It stimulates the production of pro-inflammatory cytokines by regulating the activation of various transcription factors and inflammatory signalling pathways. Targeting ER stress is an exciting possibility that can be used as a therapeutic strategy for cancer treatment. This mini review focuses on the emerging link between ER stress-induced inflammatory responses in cancer development.

Keywords:

ER stress inflammation cancer UPR response

References

  1. Berridge MJ. The endoplasmic reticulum: A multifunctional signaling organelle. Cell Calcium, Endoplasmic Reticulum as a Signalling Organelle 2002; 32(5–6): 235–249. doi: 10.1016/S0143416002001823
  2. Grandjean JMD, Wiseman RL. Small molecule strategies to harness the unfolded protein response: where do we go from here? Journal of Biological Chemistry 2020; 295(46): 15692–15711. doi: 10.1074/jbc.REV120.010218
  3. Li Y, Lu L, Zhang G, et al. The role and therapeutic implication of endoplasmic reticulum stress in inflammatory cancer transformation. American Journal of Cancer Research 2022; 12(5): 2277–2292.
  4. Hetz C, Zhang K, Kaufman RJ. Mechanism, regulation and functions of the unfolded protein response. Nature Reviews. Molecular Cell Biology 2020; 21(8): 421–438. doi: 10.1038/s41580-020-0250-z
  5. Papaioannou A, Chevet E. Driving cancer tumorigenesis and metastasis through UPR signaling. In: Wiseman RL, Haynes CM (editors). Coordinating Organismal Physiology through the Unfolded Protein Response, Current Topics in Microbiology and Immunology. Springer International Publishing, Cham; 2018; 414:159–192.
  6. Rutkowski DT, Kaufman RJ. A trip to the ER: Coping with stress. Trends in Cell Biology 2004; 14: 20–28. doi: 10.1016/j.tcb.2003.11.001
  7. Jaramillo MC, Zhang DD. The emerging role of the Nrf2–Keap1 signaling pathway in cancer. Genes & Development 2013; 27(20): 2179–2191. doi: 10.1101/gad.225680.113
  8. Koromilas AE. Roles of the translation initiation factor eIF2α serine 51 phosphorylation in cancer formation and treatment. Biochim. Biophys. Acta (BBA)—Gene Regulatory Mechanisms 2015; 1849(7): 871–880. doi: 10.1016/j.bbagrm.2014.12.007
  9. Verfaillie T, Garg AD, Agostinis P. Targeting ER stress induced apoptosis and inflammation in cancer. Cancer Letters 2013; 332(2): 249–264. doi: 10.1016/j.canlet.2010.07.016
  10. Manna SK, Babajan B, Raghavendra PB, et al. Inhibiting TRAF2- ediated activation of NF-kappaB facilitates induction of AP-1. Journal of Biological Chemistry 2010; 285(15): 11617–11627. doi: 10.1074/jbc.m109.094961
  11. Currò M, Gangemi C, Giunta ML, et al. Transglutaminase 2 is involved in amyloid-beta 1–42-induced proinflammatory activation via AP1/JNK signalling pathways in THP-1 monocytes. Amino Acids 2016; 49(3): 659–669. doi: 10.1007/s00726-016-2366-1
  12. Mahadevan NR, Rodvold J, Almanza G, Pérez AF, Wheeler MC, Zanetti M. ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner. BMC Cancer. 2011 Jun 7;11:229. doi: 10.1186/1471-2407-11-229.
  13. Swanson KV, Deng M, Ting JPY. The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nature Reviews Immunology 2019; 19(8): 477–489. doi: 10.1038/s41577-019-0165-0
  14. Carothers AM, Davids JS, Damas BC, Bertagnolli MM. Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+mouse model of colon tumorigenesis. Cancer Research 2010; 70(11): 4433–4442. doi: 10.1158/0008-5472.CAN-09-4289
  15. Liu X, Plummer SJ, Nock NL, et al. Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: Modification by lymphotoxin alpha. American Journal of Epidemiology 2006; 164(10): 984–989. doi: 10.1093/aje/kwj294
  16. Luo JL, Maeda S, Hsu LC, et al. Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAILmediated tumor regression. Cancer Cell 2004; 6(3): 297–305. doi: 10.1016/j.ccr.2004.08.012
  17. Gierach GL, Lacey JV, Schatzkin A, et al. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the national contribution of ER stress to immunogenic cancer cell death institutes of Health-AARP diet and health study. Breast Cancer Research 2008; 10(2): R38. doi: 10.1186/bcr2089
  18. Ojha R, Amaravadi RK. Targeting the unfolded protein response in cancer. Pharmacological Research 2017; 120: 258–266. doi: 10.1016/j.phrs.2017.04.003
  19. Garg AD, Krysko DV, Golab J, et al. Contribution of ER stress to immunogenic cancer cell death. In: Agostinis P, Afshin S (editors). Endoplasmic Reticulum Stress in Health and Disease. Springer; 2012.
  20. Axten JM, Romeril SP, Shu A, et al. Discovery of GSK2656157: An optimized PERK inhibitor selected for preclinical development. ACS Medicinal Chemistry Letters 2013; 4(10): 964–968. doi: 10.1021/ml400228e
  21. Atkins C, Liu Q, Minthorn E, et al. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Research 2013; 73(6): 1993–2002. doi: 10.1158/0008-5472.CAN-12-3109